152P Precision immunotherapy in carcinosarcoma: Immune-active molecular subtype identifies responders in a multicenter phase II nivolumab trial

ESMO rare cancers. 2026 Open access

Read full text
Authors: K-H. Yun, M. Kim, J. Lee, S. Kim, SJ Shin, Y.H. Lee, S.H. Kim, H.S. Kim
DOI: 10.1016/j.esmorc.2026.100358
Cited by: 0

Abstract

Carcinosarcoma is a rare, high-grade neoplasm with biphasic components and poor prognosis. Given its heterogeneity, identifying subgroups benefiting from immunotherapy is critical. We evaluated nivolumab efficacy in recurrent/metastatic carcinosarcoma and identified predictive biomarkers via RNA profiling.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Metastasis and carcinoma case studies Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100358–100358
Publication date
1 March 2026
Language
EN